At a glance
ClinicalIndex Comparison RecordPhase 4Completed· 42 enrolled
Drug / intervention
Triamcinolone Acetonide +1 moredrug
Likely dose
Ayr saline nasal mist 110mcgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
The Effectiveness of Nasal Corticosteroids Versus Placebo in Nasal Obstruction in Patients With Nasal Septal Deviation
In Brief
A Phase 4 clinical trial evaluating Triamcinolone Acetonide and Ayr saline nasal mist for Nasal Obstruction. Completed, enrolled 42 participants across 1 site.
Detailed Summary
The purpose of this project is to determine if intranasal corticosteroids have an effect on nasal obstruction in patients with nasal septal deviation.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsNasal Obstruction
CountriesUnited States
Collaborators--
Timeline
Phase 4CompletedFinished
2017201820192020202120222023202420252026
Enrollment StartAug 2016
First PostedAug 2016
Primary CompletionAug 2019
TodayJul 2026
First PostedAug 24, 2016
Enrollment StartAug 1, 2016
Primary CompletionAug 15, 2019
TodayJul 2, 2026
Enrollment to primary: 3.0 yearsPosted 9.9 years ago
Interventions
Triamcinolone Acetonidedrug
2 sprays sprayed to both nostrils daily for 42 days.
Ayr saline nasal mistdrug
110mcg (2 sprays) sprayed to both nostrils daily for 42 days.